In summary, our study demonstrates for the first time that: 1) MiR-185 and 342 inhibit the expression of SREBP-1 and SREBP-2 as well as their downstream regulated genes, and reprogram lipogenesis and cholesterogenesis in prostate cancer cells. This evidence concerns the gene SREBF1 and prostate cancer.